BERKELEY, Calif. and HEIDELBERG, Germany, Oct. 2, 2006 (PRIMEZONE) -- XOMA Ltd. (Nasdaq:XOMA) and Affimed Therapeutics AG announced today that they have signed a cross-license and collaboration agreement for antibody-related technologies. Financial terms were not disclosed.
